Bristol Myers Squibb - News
WEBSep 18, 2024 — Bristol Myers Squibb to Present Data at ESMO Demonstrating Ongoing Leadership in Immuno-Oncology and Progression of Assets from Its Differentiated Research Platforms
Bristol Myers Squibb - Bristol Myers Squibb to Acquire Turning …
WEBJun 3, 2022 — Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company. Acquisition Brings Repotrectinib, a Potential Best-in-Class, Next-Generation ROS1/NTRK Inhibitor with Differentiated Duration of Response for Patients with ROS1-positive First-Line Non-Small Cell Lung Cancer; Expected to …
Bristol Myers Squibb - Bristol Myers Squibb Adds Premier ...
WEBDec 26, 2023 — Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio. Transaction Brings RayzeBio’s Differentiated Actinium-Based Radiopharmaceutical Platform, Including Rich Pipeline of Multiple Drug Development Programs, to Bristol Myers Squibb’s Leading Oncology Franchise. Lead Program, RYZ101, in …
Bristol Myers Squibb Strengthens Neuroscience Portfolio with ...
WEBDec 22, 2023 — Bristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics. Transaction Delivers KarXT, a First-in-Class M1 / M4 Muscarinic Receptor Agonist, with Differentiated Efficacy and Safety. KarXT Is a Potential First-in-Class Treatment for Schizophrenia and as an Adjunctive Therapy, and First-in …
Bristol Myers Squibb - Bristol Myers Squibb Completes Acquisition …
WEBJan 23, 2024 — PRINCETON, N.J.-- (BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc. ® (“Mirati”).
Bristol Myers Squibb Completes Acquisition of Turning Point ...
WEBAug 17, 2022 — Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. (“Turning Point”), in an all-cash transaction.
Bristol Myers Squibb - Bristol Myers Squibb Completes Acquisition …
WEBMar 18, 2024 — Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio. KarXT, Karuna’s Lead Asset, Is a Potential First-in-Class Treatment for Schizophrenia with Multi-Billion Dollar Sales Potential Across Multiple Indications. PRINCETON, N.J.-- (BUSINESS WIRE)-- …
Bristol Myers Squibb Strengthens and Diversifies Oncology …
WEBOct 8, 2023 — Through this acquisition, Bristol Myers Squibb will add KRAZATI, an important lung cancer medicine, to its commercial portfolio. The company gains access to several promising clinical assets that complement its oncology pipeline and are strong candidates for single agent development and combination strategies.
Bristol Myers Squibb - KRAZATI (adagrasib) Demonstrated …
WEBJun 1, 2024 — PRINCETON, N.J.--(BUSINESS WIRE)-- Bristol Myers Squibb (NYSE: BMY) today announced results from the Phase 3 KRYSTAL-12 study evaluating KRAZATI ® (adagrasib) compared to standard of care chemotherapy in patients with locally advanced or metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC) who had previously received platinum-based ...
Bristol Myers Squibb - Bristol-Myers Squibb Completes …
WEBBristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.
Skip to content